RISS 학술연구정보서비스

검색
다국어 입력

http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.

변환된 중국어를 복사하여 사용하시면 됩니다.

예시)
  • 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
  • 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
닫기
    인기검색어 순위 펼치기

    RISS 인기검색어

      검색결과 좁혀 보기

      선택해제

      오늘 본 자료

      • 오늘 본 자료가 없습니다.
      더보기
      • 무료
      • 기관 내 무료
      • 유료
      • KCI등재

        Comparison of different classes of drugs for Management of Acute Coronary Syndrome (ACS): A brief communication

        Malik, Jonaid Ahmad,Maqbool, Mudasir,Hajam, Tawseef Ahmad,Khan, Muhammad Abrar,Zehravi, Mehrukh Cellmed Orthocellular Medicine and Pharmaceutical 2021 셀메드 (CellMed) Vol.11 No.2

        Acute coronary syndrome (ACS) is a class of conditions consisting of NSTEMI (non-ST-elevated myocardial infarction), STEMI (ST-elevated myocardial infarction), unstable angina, ranging from myocardial ischaemic states, as well as there is usually a mismatch with respect to both blood supply and blood demand marked by chest pain. Indian patients with ACS have a higher STEMI score than patients of established countries'. Since most of these patients were poor, they were less likely to receive adequate therapy and had a higher death rate of 30 days. In India, ACS patients appear to be young from low socioeconomic backgrounds and have higher ST-elevated MI ratesthan do patients of established countries'. In India, patients get late medical treatment and inadequate access to proven therapies. Hypertension, hyperlipidemia, diabetes, obesity, cigarette use and a family history of atherosclerotic disease are important risk factors attributed to ACS. Most of the general therapy for ACS focuses on reducing myocardial ischemia and pain suppression. Because of the time dependence of the condition, the onset of signs and arrival at the hospital for the treatment of ACS is very important. This time gap between the onset of symptoms and hospital appearance is larger in India relative to western countries. This paper will concentrate on ACS management and a brief on comparative study of various groups of drugs available with regard to clinical trials and guidelines, respectively.

      • KCI등재

        Supplementation of fly ash improves growth, yield, biochemical, and enzymatic antioxidant response of chickpea (Cicer arietinum L.)

        Mohammad Haris,Moh Sajid Ansari,Abrar Ahmad Khan 한국원예학회 2021 Horticulture, Environment, and Biotechnology Vol.62 No.5

        This research was investigated to assess the eff ect of fl y ash (FA) on the growth, yield, biochemical attributes, and enzymaticantioxidant response of chickpea ( Cicer arietinum L. cv. Avrodhi). After evaluating soil and FA nutrient status byenergy-dispersive X-ray spectroscopy (EDX), diff erent concentrations of FA with soil were applied (5, 10, 15, 20, 25,and 30%). Chickpea plants grown at all FA-amended soil concentrations demonstrate signifi cant improvement ( p ≤ 0.05)in growth and yield biomass. Exhibition of enhancement in biochemical attributes such as photosynthetic pigments(chlorophyll a and b, total chlorophyll, and total carotenoid by 16.83, 24.50, 19.13, and 21.74%), total protein (48.54%),leghemoglobin (42.39%), nitrate reductase activity (18.35%), proline content (28.16%), and antioxidant enzymes activities. Moreover, an improvement in the stomatal pore of the FA treated plant also noticed by a scanning electron microscope(SEM). Overall, the fi ndings of this study indicate that the supplementation of FA contributed to increment inthese attributes at all the concentrations compared with control (without FA) ‘but maximally ~ up to FA 20%.’ However,plant growth and yield biomass decreased above the concentration of FA 20% because chickpea can balanced nutrientseffi ciency up to FA 20%.

      연관 검색어 추천

      이 검색어로 많이 본 자료

      활용도 높은 자료

      해외이동버튼